Alyeska Investment Group
AMLX icon

Alyeska Investment Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Alyeska Investment Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9M Buy
+1,053,015
New +$16.3M 0.05% 343
2025
Q2 		– Sell
-750,412
Closed -$2.66M – 553
2025
Q1 		$2.66M Sell
750,412
-73,008
-9% -$260K 0.01% 404
2024
Q4 		$3.11M Sell
823,420
-1,200,000
-59% -$5.65M 0.01% 438
2024
Q3 		$6.56M Buy
2,023,420
+200,000
+11% +$450K 0.03% 327
2024
Q2 		$3.46M Buy
1,823,420
+814,813
+81% +$1.58M 0.02% 371
2024
Q1 		$2.86M Buy
+1,008,607
New +$13.2M 0.02% 360
2023
Q4 		– Sell
-120,157
Closed -$2.2M – 519
2023
Q3 		$2.2M Sell
120,157
-200,000
-62% -$4.23M 0.01% 384
2023
Q2 		$6.91M Buy
320,157
+68,750
+27% +$1.86M 0.05% 307
2023
Q1 		$7.38M Buy
251,407
+201,407
+403% +$7M 0.06% 272
2022
Q4 		$1.85M Buy
+50,000
New +$1.77M 0.02% 326

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Alyeska Investment Group's AMLX Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 1,053,015 shares worth $18.9M. The stake represents 0.05% of the portfolio and ranks #343 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in AMLX as recently as Q1 2025.

Alyeska Investment Group first reported a position in AMLX in Q4 2022 and has held it in 10 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Alyeska Investment Group held 1,053,015 shares of Amylyx Pharmaceuticals worth $18.9M as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Alyeska Investment Group position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.05% of Alyeska Investment Group's portfolio in Q2 2026, its #343 holding.
  • Alyeska Investment Group first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.